Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05669482 · ClinicalTrials.gov registry record · Phase 1

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

A Phase 1 study of Metastatic Cancer and Pancreas Cancer, sponsored by Verastem.

Active
Registry status
Phase 1
Development phase
40
Enrollment target
12
Study locations

NCT05669482 is a Phase 1 study of Metastatic Cancer and Pancreas Cancer that is active but no longer recruiting, run by Verastem. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05669482, a Phase 1 study of Metastatic Cancer and Pancreas Cancer, is active but no longer recruiting, sponsored by Verastem.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
12
Study locations

Study Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.

Conditions Studied

Metastatic Cancer Pancreas Cancer KRAS Activating Mutation Neoplasms Pancreatic Malignant Neoplasm of Pancreas

Interventions

  • DRUG avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel

Study Locations (12)

New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
  • New York Presbyterian/Weill-Cornell Medical Center - New York
  • Memorial Sloan Kettering Cancer Center - New York

Washington

  • Virginia Mason Medical Center - Seattle
  • Fred Hutchinson Cancer Center - Seattle

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Illinois

  • University of Chicago - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • University of Michigan Cancer Center - Ann Arbor

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-03-22
Est. Completion 2027-08-31
Phase Phase 1

Sponsor

Verastem

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05669482

The ClinicalTrials.gov registry entry for NCT05669482 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel is the first listed.

NCT05669482 reports 12 study locations spanning 9 distinct geographic areas - top geographies include New York, Washington, California.

Frequently Asked Questions

What is clinical trial NCT05669482 about?

NCT05669482 is a clinical study titled "Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.

What is the current status of trial NCT05669482?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-03-22. Estimated completion is 2027-08-31.

What conditions does trial NCT05669482 study?

This clinical trial studies the following conditions: Metastatic Cancer, Pancreas Cancer, KRAS Activating Mutation, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas.

What interventions are being tested in trial NCT05669482?

The interventions under investigation include: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel (DRUG).

Who is sponsoring clinical trial NCT05669482?

This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05669482 being conducted?

This trial has 12 study locations across California, Illinois, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Cancer

All registered trials for this condition

Pancreas Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.